NOS inhibitor treatment significantly suppressed STAT3 S-nitrosylation, promoted STAT3 phosphorylation and enhanced viability of pancreatic cancer cells, further indicating the essential roles of S-nitrosylation in PDAC pathogenesis. The gene discussed is STAT3; the disease is familial pancreatic carcinoma.